HIMS Stock Eyes Big Monthly Win: Novo Nordisk Calls Hims & Hers One Of Its Most ‘Voluminous’ Telehealth Partners
Hims partnered with Novo Nordisk in March to offer branded weight-loss drugs. Employer GLP-1 coverage cuts could push…
HIMS Stock Gained Nearly 6% On Wednesday — Barclays Sees Breakout Potential After Novo Partnership
On March 9, Novo Nordisk said it will sell its blockbuster Wegovy and Ozempic drugs through Hims &…
HIMS Stock Extends 3-Day Rally: Hims & Hers Targets GLP-1 Gold Rush In Canada After Novo Nordisk Patent Expiry
Hims launched generic Semaglutide in Canada, opening a lower-cost alternative to Novo Nordisk’s Ozempic and Wegovy. Health Canada…
HIMS Stock Drops on Q1 Miss as Novo Nordisk GLP-1 Pivot Lifts Costs
Shares of telehealth provider Hims & Hers Health NYSE: HIMS sold off sharply following disappointing Q1 FY2026 financial…
Hims & Hers raises 2026 revenue forecast on strong demand for personalized care
May 11 (Reuters) – Hims & Hers Health raised its 2026 revenue forecast on Monday, betting on increased…
Q1 FY2026 Earnings Preview After FDA Move and NVO Collaboration
Healthcare stocks have struggled in 2026. With a year-to-date (YTD) loss of about 6%, that corner of the…
FDA GLP-1 Compounding Proposal Boosts LLY, NVO, and HIMS Stock
Eli Lilly and Company NYSE: LLY and Novo Nordisk A/S NYSE: NVO are two weight-loss and diabetes drug…
Could the Novo Nordisk Deal Be the Turning Point?
Quick Read JPMorgan initiated Hims & Hers (HIMS) with Overweight and $35 target, citing Novo Nordisk (NVO) partnership…
Hims & Hers Rallies 9% as Investors Bet Big on Peptide Pipeline and Novo Nordisk Deal
Hims & Hers (HIMS) shares surged on FDA peptide tailwinds and a Novo Nordisk partnership to distribute branded…
Hims & Hers Health (HIMS) Is Up 8.3% After Expanding Novo Nordisk GLP-1 Partnership And Launching New Weight-Loss Membership
In late March 2026, Hims & Hers Health, Inc. announced a renewed collaboration with Novo Nordisk to offer…
Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers
Starting today, eligible customers can access a broad assortment of treatment options, including the only FDA-approved GLP-1 weight…
Hims & Hers Health (HIMS) Valuation After Novo Nordisk Weight Loss Deal And Product Exit
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…